The ADNI study actively supports the investigation and development of treatments that slow or stop the progression of Alzheimer’s disease (AD). Researchers at over 60 clinical sites in the USA and Canada collect data to study the progression of AD in the human brain across normal aging, mild cognitive impairment (MCI), and Alzheimer’s disease and dementia. Click here to learn more about the history of ADNI and the researchers who lead the study.
To improve how doctors diagnose
patients with Alzheimer's disease
To provide data to researchers
around the world
Alzheimer’s disease (AD) is an irreversible neurodegenerative disease that results in a loss of mental (cognitive) function caused by the deterioration of brain tissue and affects millions of people worldwide.
The ADNI study tracks the progression of the disease using biological markers (biomarkers; for example, chemicals found in blood, or changes to the brain observed in MRI and PET scans), together with clinical measures (cognitive and neuropsychological tests), to assess the brain’s structure and function over the course of three disease states (cognitively normal/unimpaired, mild cognitive impairment, dementia). ADNI provides study data and biospecimens (samples) to qualified researchers worldwide. Click here to learn more about ADNI data and samples.
By studying brain aging in older adults and sharing the knowledge we gain, we can move towards earlier diagnosis, better treatments, and an end to Alzheimer's disease and dementia. Click here to learn more about Alzheimer’s disease and participating in ADNI.
Primary Goal
Funding
Duration
Cohort
2004 – 2010
Develop biomarkers as outcome measures for clinical trials
$40 million federal (NIA), $27 million industry and foundation
5 years/October 2004
200 elderly controls
400 MCI
200 AD
2009 – 2011
Examine biomarkers in earlier stages of disease
$24 million American Recovery Act funds
2 years/September 2009
Existing ADNI1 +
200 early MCI
2011 – 2016
Develop biomarkers as predictors of cognitive decline, and as outcome measures
$40 million federal (NIA), $27 million industry and foundation
5 years/September 2011
Existing ADNI1 and ADNI Go
150 elderly controls
100 elderly MCI
150 late MCI
150 AD
2016-2022
Study the use of tau PET and functional imaging techniques in clinical trails
$40 million federal (NIA), up to $20 million industry and foundation
5 years/September 2016
Existing ADNI1,ADNI Go, ADNI2 +
133 elderly controls
151 MCI
87 AD
2022 and beyond
Improve representation of historically underrepresented groups in AD research
$147 million federal (NIA)
5 years/September 2022
Existing ADNI 1, ADNI-GO, ADNI-2, ADNI-3 +
200 elderly controls,
200 MCI,
100 AD/DEM
ADNI study data are hosted on the Image and Data Archive (IDA) by the Laboratory of Neuro Imaging (LONI) at the University of Southern California. Qualified researchers worldwide can submit an online data access request and then begin using ADNI data.
Biospecimens collected from ADNI participants are made available to researchers with permission from the National Institute on Aging (NIA) and the ADNI Resource Allocation and Review Committees (RARCs).
Several Alzheimer’s disease (AD) initiatives have repurposed the study methods and research network developed through ADNI. By partnering with related studies of AD, ADNI researchers can access data from a larger study cohort, thereby enhancing their scientific results.
The Health Equity Scholars Program (HESP) provides future investigators in the field of Alzheimer’s Disease and Related Dementias (ADRDs) with the knowledge, skills and resources to become culturally competent and proficient researchers. HESP provides a tailored mentored training approach to advance career success and satisfaction among its trainees.
This research was supported by grant number U19AG024904 from the National Institute on Aging, part of the National Institutes of Health.
Currently convened by the Alzheimer’s Association
The Foundation for the National Institutes of Health previously convened the PPSB Partners generously for 18 years.
If you are 55 to 90 years of age you may be able to participate. Participation is free and no medication is involved.
Join
